Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported a combination of RSU vesting and a related tax sale. On February 13, 2026, he acquired 30,031 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing his directly held common stock.
On February 18, 2026, he sold 16,644 shares of common stock in an open‑market transaction at a weighted average price of $5.8233 per share to cover withholding taxes following the RSU vesting, under a pre‑existing automatic sales instruction that is not a discretionary trade. After these transactions, he directly owned 235,405 shares of common stock and 60,063 RSUs that vest over four years from the February 13, 2024 grant date.
Solid Biosciences filed a Form 144 reporting a proposed sale of Common Stock tied to the settlement of vested restricted stock units on 02/18/2026. The filing lists proposed/settled share movements including examples of prior sales by a selling holder, including Brooks Gabriel: 28,335 shares and 12,616 shares.
The notice ties the 02/18/2026 entry to compensation (RSU settlement); proceeds and specific distribution methods are shown for prior sales in the excerpt.
Cumbo Alexander filed a Form 144 reporting proposed sales of Common Stock. The notice lists three transactions: 12/03/2025 sale of 10,808 shares for $55,228.88, 02/02/2026 sale of 80,258 shares for $516,612.72, and 02/04/2026 sale of 48,913 shares for $315,079.69.
The excerpt also shows the settlement of 16,644 vested restricted stock units on 02/18/2026 reported as issuer compensation.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported insider equity activity involving restricted stock units and related tax sales. On February 13, 2026, she acquired 8,125 shares of common stock through the exercise of restricted stock units at a price of $0.00 per share. On February 18, 2026, she sold 4,134 shares of common stock at a weighted average price of $5.8233 per share, with actual sale prices ranging from $5.23 to $6.14, to cover withholding taxes following RSU vesting under a pre-established automatic sell-to-cover instruction. After these transactions, she held 74,318 shares of common stock and 16,250 restricted stock units.
Harahan Jessie submitted a Form 144 to sell 4,134 shares of common stock related to the settlement of vested restricted stock units, with settlement dated 02/18/2026. The filing lists prior dispositions in the past three months of 4,483 shares on 12/03/2025, 26,535 shares on 02/02/2026, and 12,348 shares on 02/04/2026.
Solid Biosciences Inc. director Ilan Ganot reported a small net sale of shares mainly tied to restricted stock unit vesting and tax withholding.
An entity associated with his wife sold 2,658 shares of common stock in an open-market transaction at a weighted average price of $5.8233 per share, with individual trades ranging from $5.23 to $6.14. According to the disclosure, this sale was made to cover withholding taxes after previously granted restricted stock units vested and followed a durable automatic sales instruction adopted by Ms. Ganot, so it was not a discretionary trade.
On the same date, 4,861 restricted stock units held by Ms. Ganot converted into an equal number of common shares at no exercise price, reflecting the one-for-one RSU-to-share ratio. After these transactions, Mr. Ganot’s reported holdings include shares held individually, jointly with his spouse, and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences submitted a Form 144 reporting a proposed sale of 3,616 shares of common stock to settle vested restricted stock units on 02/18/2026.
The filing lists prior sales by the reporting person: 2,701 shares on 12/03/2025, 26,250 shares on 02/02/2026, and 10,905 shares on 02/04/2026. The securities are listed on NASDAQ.
Solid Biosciences (SLDB) reporting person submitted a Form 144 to sell Common Stock tied to the settlement of vested restricted stock units held indirectly through his spouse on 02/18/2026. The filing lists prior sales in 01/05/2026, 01/28/2026, and 02/04/2026 with share amounts and aggregate values included.
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported both an RSU vesting and a related stock sale. On February 13, 2026, he acquired 7,187 shares of common stock upon the exercise of 7,187 restricted stock units at $0.00 per share, increasing his direct common stock holdings to 76,254 shares.
On February 18, 2026, Herzich then sold 3,616 common shares in an open-market transaction at a weighted average price of $5.8233 per share, with actual prices ranging from $5.23 to $6.14. The company states this sale was solely to cover tax withholding following RSU vesting, under a pre-established automatic sales instruction, and does not represent a discretionary trade by Herzich. After the sale, he directly held 72,638 common shares.
Solid Biosciences Chief Operating Officer David T. Howton reported routine equity activity involving restricted stock units and related share sales. On February 13, 2026, RSUs granted on February 13, 2024 vested, resulting in the acquisition of 14,687 shares of common stock through a derivative conversion at a price of $0.00 per share. A corresponding RSU position of 14,687 units was reduced, leaving 29,376 RSUs outstanding. On February 18, 2026, 7,469 common shares were sold in the open market at a weighted average price of $5.8233 per share to cover withholding taxes following this vesting, under a durable automatic sales instruction adopted on August 16, 2024, so the sale was not a discretionary trade. After these transactions, Howton held 105,077 shares of common stock directly.